Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.
Identifieur interne : 001D20 ( Ncbi/Merge ); précédent : 001D19; suivant : 001D21Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.
Auteurs : Javier Vega-Ramos [Australie] ; Antoine Roquilly [France] ; Karim Asehnoune [France] ; Jose A. Villadangos [Australie]Source :
- Current opinion in pharmacology [ 1471-4973 ] ; 2014.
Descripteurs français
- KwdFr :
- Animaux, Anti-inflammatoires (usage thérapeutique), Cellules dendritiques (), Cellules dendritiques (immunologie), Conception de médicament, Facteurs immunologiques (usage thérapeutique), Humains, Inflammation (immunologie), Inflammation (métabolisme), Inflammation (traitement médicamenteux), Interactions hôte-pathogène (), Maladies transmissibles (immunologie), Maladies transmissibles (métabolisme), Maladies transmissibles (traitement médicamenteux), Médiateurs de l'inflammation (métabolisme), Présentation d'antigène (), Récepteurs immunologiques (), Récepteurs immunologiques (métabolisme), Transduction du signal ().
- MESH :
- immunologie : Cellules dendritiques, Inflammation, Maladies transmissibles.
- métabolisme : Inflammation, Maladies transmissibles, Médiateurs de l'inflammation, Récepteurs immunologiques.
- traitement médicamenteux : Inflammation, Maladies transmissibles.
- usage thérapeutique : Anti-inflammatoires, Facteurs immunologiques.
- Animaux, Cellules dendritiques, Conception de médicament, Humains, Interactions hôte-pathogène, Présentation d'antigène, Récepteurs immunologiques, Transduction du signal.
English descriptors
- KwdEn :
- Animals, Anti-Inflammatory Agents (therapeutic use), Antigen Presentation (drug effects), Communicable Diseases (drug therapy), Communicable Diseases (immunology), Communicable Diseases (metabolism), Dendritic Cells (drug effects), Dendritic Cells (immunology), Drug Design, Host-Pathogen Interactions (drug effects), Humans, Immunologic Factors (therapeutic use), Inflammation (drug therapy), Inflammation (immunology), Inflammation (metabolism), Inflammation Mediators (metabolism), Receptors, Immunologic (drug effects), Receptors, Immunologic (metabolism), Signal Transduction (drug effects).
- MESH :
- chemical , drug effects : Receptors, Immunologic.
- chemical , metabolism : Inflammation Mediators, Receptors, Immunologic.
- chemical , therapeutic use : Anti-Inflammatory Agents, Immunologic Factors.
- drug effects : Antigen Presentation, Dendritic Cells, Host-Pathogen Interactions, Signal Transduction.
- drug therapy : Communicable Diseases, Inflammation.
- immunology : Communicable Diseases, Dendritic Cells, Inflammation.
- metabolism : Communicable Diseases, Inflammation.
- Animals, Drug Design, Humans.
Abstract
Antigen presentation by dendritic cells (DC) is regulated directly by pathogen-associated or cell death-associated cues, or indirectly by immunomodulatory molecules produced during infection or tissue damage. DC modulation by direct encounter of pathogen-associated compounds has been thoroughly studied; the effects of molecules associated with cell death are less well characterized; modulation by secondary signals remain poorly understood. In this review we describe recent studies on the role of these three categories of immunomodulatory compounds on DC. We conclude that characterization of the role of secondary immunomodulators is an area in dare need of further study. The outcomes of this endeavor will be new opportunities for the development of better vaccines and compounds applicable to the therapeutic immunomodulation of DC function.
DOI: 10.1016/j.coph.2014.07.013
PubMed: 25128781
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003563
- to stream PubMed, to step Curation: 003450
- to stream PubMed, to step Checkpoint: 003450
Links to Exploration step
pubmed:25128781Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.</title><author><name sortKey="Vega Ramos, Javier" sort="Vega Ramos, Javier" uniqKey="Vega Ramos J" first="Javier" last="Vega-Ramos">Javier Vega-Ramos</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Roquilly, Antoine" sort="Roquilly, Antoine" uniqKey="Roquilly A" first="Antoine" last="Roquilly">Antoine Roquilly</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Asehnoune, Karim" sort="Asehnoune, Karim" uniqKey="Asehnoune K" first="Karim" last="Asehnoune">Karim Asehnoune</name><affiliation wicri:level="4"><nlm:affiliation>Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement><settlement type="city">Nantes</settlement></placeName><orgName type="university">Université de Nantes</orgName></affiliation></author><author><name sortKey="Villadangos, Jose A" sort="Villadangos, Jose A" uniqKey="Villadangos J" first="Jose A" last="Villadangos">Jose A. Villadangos</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Department of Biochemistry and Molecular Biology, Bio21 Institute, The University of Melbourne, Parkville, Australia. Electronic address: j.villadangos@unimelb.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Department of Biochemistry and Molecular Biology, Bio21 Institute, The University of Melbourne, Parkville</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25128781</idno><idno type="pmid">25128781</idno><idno type="doi">10.1016/j.coph.2014.07.013</idno><idno type="wicri:Area/PubMed/Corpus">003563</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003563</idno><idno type="wicri:Area/PubMed/Curation">003450</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003450</idno><idno type="wicri:Area/PubMed/Checkpoint">003450</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003450</idno><idno type="wicri:Area/Ncbi/Merge">001D20</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.</title><author><name sortKey="Vega Ramos, Javier" sort="Vega Ramos, Javier" uniqKey="Vega Ramos J" first="Javier" last="Vega-Ramos">Javier Vega-Ramos</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Roquilly, Antoine" sort="Roquilly, Antoine" uniqKey="Roquilly A" first="Antoine" last="Roquilly">Antoine Roquilly</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement><settlement type="city">Melbourne</settlement></placeName><orgName type="university">Université de Melbourne</orgName></affiliation></author><author><name sortKey="Asehnoune, Karim" sort="Asehnoune, Karim" uniqKey="Asehnoune K" first="Karim" last="Asehnoune">Karim Asehnoune</name><affiliation wicri:level="4"><nlm:affiliation>Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement><settlement type="city">Nantes</settlement></placeName><orgName type="university">Université de Nantes</orgName></affiliation></author><author><name sortKey="Villadangos, Jose A" sort="Villadangos, Jose A" uniqKey="Villadangos J" first="Jose A" last="Villadangos">Jose A. Villadangos</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Department of Biochemistry and Molecular Biology, Bio21 Institute, The University of Melbourne, Parkville, Australia. Electronic address: j.villadangos@unimelb.edu.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Department of Biochemistry and Molecular Biology, Bio21 Institute, The University of Melbourne, Parkville</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author></analytic><series><title level="j">Current opinion in pharmacology</title><idno type="eISSN">1471-4973</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Antigen Presentation (drug effects)</term><term>Communicable Diseases (drug therapy)</term><term>Communicable Diseases (immunology)</term><term>Communicable Diseases (metabolism)</term><term>Dendritic Cells (drug effects)</term><term>Dendritic Cells (immunology)</term><term>Drug Design</term><term>Host-Pathogen Interactions (drug effects)</term><term>Humans</term><term>Immunologic Factors (therapeutic use)</term><term>Inflammation (drug therapy)</term><term>Inflammation (immunology)</term><term>Inflammation (metabolism)</term><term>Inflammation Mediators (metabolism)</term><term>Receptors, Immunologic (drug effects)</term><term>Receptors, Immunologic (metabolism)</term><term>Signal Transduction (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anti-inflammatoires (usage thérapeutique)</term><term>Cellules dendritiques ()</term><term>Cellules dendritiques (immunologie)</term><term>Conception de médicament</term><term>Facteurs immunologiques (usage thérapeutique)</term><term>Humains</term><term>Inflammation (immunologie)</term><term>Inflammation (métabolisme)</term><term>Inflammation (traitement médicamenteux)</term><term>Interactions hôte-pathogène ()</term><term>Maladies transmissibles (immunologie)</term><term>Maladies transmissibles (métabolisme)</term><term>Maladies transmissibles (traitement médicamenteux)</term><term>Médiateurs de l'inflammation (métabolisme)</term><term>Présentation d'antigène ()</term><term>Récepteurs immunologiques ()</term><term>Récepteurs immunologiques (métabolisme)</term><term>Transduction du signal ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Immunologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Inflammation Mediators</term><term>Receptors, Immunologic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Immunologic Factors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Antigen Presentation</term><term>Dendritic Cells</term><term>Host-Pathogen Interactions</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Communicable Diseases</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cellules dendritiques</term><term>Inflammation</term><term>Maladies transmissibles</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Communicable Diseases</term><term>Dendritic Cells</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Communicable Diseases</term><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Inflammation</term><term>Maladies transmissibles</term><term>Médiateurs de l'inflammation</term><term>Récepteurs immunologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Inflammation</term><term>Maladies transmissibles</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term><term>Facteurs immunologiques</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Drug Design</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules dendritiques</term><term>Conception de médicament</term><term>Humains</term><term>Interactions hôte-pathogène</term><term>Présentation d'antigène</term><term>Récepteurs immunologiques</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Antigen presentation by dendritic cells (DC) is regulated directly by pathogen-associated or cell death-associated cues, or indirectly by immunomodulatory molecules produced during infection or tissue damage. DC modulation by direct encounter of pathogen-associated compounds has been thoroughly studied; the effects of molecules associated with cell death are less well characterized; modulation by secondary signals remain poorly understood. In this review we describe recent studies on the role of these three categories of immunomodulatory compounds on DC. We conclude that characterization of the role of secondary immunomodulators is an area in dare need of further study. The outcomes of this endeavor will be new opportunities for the development of better vaccines and compounds applicable to the therapeutic immunomodulation of DC function.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25128781</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>07</Day></DateCreated><DateCompleted><Year>2015</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4973</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current opinion in pharmacology</Title><ISOAbbreviation>Curr Opin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.</ArticleTitle><Pagination><MedlinePgn>64-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.coph.2014.07.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1471-4892(14)00088-5</ELocationID><Abstract><AbstractText>Antigen presentation by dendritic cells (DC) is regulated directly by pathogen-associated or cell death-associated cues, or indirectly by immunomodulatory molecules produced during infection or tissue damage. DC modulation by direct encounter of pathogen-associated compounds has been thoroughly studied; the effects of molecules associated with cell death are less well characterized; modulation by secondary signals remain poorly understood. In this review we describe recent studies on the role of these three categories of immunomodulatory compounds on DC. We conclude that characterization of the role of secondary immunomodulators is an area in dare need of further study. The outcomes of this endeavor will be new opportunities for the development of better vaccines and compounds applicable to the therapeutic immunomodulation of DC function.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vega-Ramos</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roquilly</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asehnoune</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratoire UPRES EA 3826 "Thérapeutiques cliniques et expérimentales des infections", Faculte de Médecine, Université de Nantes, France; Service d'Anesthésie Réanimation Chirurgicale, Hôtel Dieu, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villadangos</LastName><ForeName>Jose A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Pakville, Australia; Department of Biochemistry and Molecular Biology, Bio21 Institute, The University of Melbourne, Parkville, Australia. Electronic address: j.villadangos@unimelb.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Pharmacol</MedlineTA><NlmUniqueID>100966133</NlmUniqueID><ISSNLinking>1471-4892</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017951" MajorTopicYN="N">Antigen Presentation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="N">Communicable Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25128781</ArticleId><ArticleId IdType="pii">S1471-4892(14)00088-5</ArticleId><ArticleId IdType="doi">10.1016/j.coph.2014.07.013</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Pays de la Loire</li><li>Victoria (État)</li></region><settlement><li>Melbourne</li><li>Nantes</li></settlement><orgName><li>Université de Melbourne</li><li>Université de Nantes</li></orgName></list><tree><country name="Australie"><region name="Victoria (État)"><name sortKey="Vega Ramos, Javier" sort="Vega Ramos, Javier" uniqKey="Vega Ramos J" first="Javier" last="Vega-Ramos">Javier Vega-Ramos</name></region><name sortKey="Villadangos, Jose A" sort="Villadangos, Jose A" uniqKey="Villadangos J" first="Jose A" last="Villadangos">Jose A. Villadangos</name></country><country name="France"><region name="Pays de la Loire"><name sortKey="Roquilly, Antoine" sort="Roquilly, Antoine" uniqKey="Roquilly A" first="Antoine" last="Roquilly">Antoine Roquilly</name></region><name sortKey="Asehnoune, Karim" sort="Asehnoune, Karim" uniqKey="Asehnoune K" first="Karim" last="Asehnoune">Karim Asehnoune</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001D20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:25128781
|texte= Modulation of dendritic cell antigen presentation by pathogens, tissue damage and secondary inflammatory signals.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:25128781" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |